KRTX | Jotup

Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update

Retrieved on:

Thursday, February 22, 2024

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.

Key Points:

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a general business update.
Results from the EMERGENT-2 trial published in The Lancet in December 2023.
Announced positive results from the Phase 1b Ambulatory Blood Pressure Monitoring trial in schizophrenia in the fourth quarter of 2023.
Presented additional data from the EMERGENT program at the 2023 Neuroscience Education Institute (NEI) Congress and the CNS Summit in the fourth quarter of 2023.

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

Retrieved on:

Wednesday, February 14, 2024

Class Action Lawsuit, Professional Services, Legal, KSF, BMY, KRTX, Sale, Therapy, Bristol Myers Squibb

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY).

Key Points:

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY).
Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER ALERT: Juan Monteverde Encourages the Shareholders of FGH, KRTX, VIA, PGTI to Take Action

Retrieved on:

Wednesday, January 24, 2024

Bristol Myers Squibb, Monteverde, FGH, Therapy, Empire, PGTI, FG, KRTX, Sale, VIA, Security (finance)

Under the terms of the agreement, FGH shareholders will receive one share of FG Financial common stock per share they own.

Key Points:

Under the terms of the agreement, FGH shareholders will receive one share of FG Financial common stock per share they own.
Under the terms of the agreement, KRTX shareholders will receive $330.00 in cash per share they own.
Under the terms of the agreement, VIA shareholders will receive $11.00 in cash per share they own.
Under the terms of the agreement, PGTI shareholders will receive $7.50 in common shares of Masonite and $33.50 in cash per share they own.

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans

Retrieved on:

Wednesday, January 24, 2024

KarXT, Food, DSM-IV codes, Drug development, SIGMAR1, Rett syndrome, Disease, KRTX, Alzheimer's disease, Central nervous system, Frontotemporal dementia, Doctor of Philosophy, Therapy, Deficit spending, Treatment, Pharmacology, Trial of the century, CNS, Pharmaceutical industry

The results from this PK evaluation demonstrated that ANAVEX®3-71, at single ascending doses of 5 to 200 mg, is linear, dose proportional, and time invariant.

Key Points:

The results from this PK evaluation demonstrated that ANAVEX®3-71, at single ascending doses of 5 to 200 mg, is linear, dose proportional, and time invariant.
Food had no effect on the PK of ANAVEX®3-71.
This data also expands the safety objectives met in this first-in-human study of ANAVEX®3-71, further supporting its drug development program.
Phase 2 clinical trial in Schizophrenia with ANAVEX®3-71.”
The paper can be accessed online at: https://pubmed.ncbi.nlm.nih.gov/38073274/ .

ALERT: Juan Monteverde Encourages the Shareholders of VIA, PGTI, FGH, KRTX to Take Action

Retrieved on:

Saturday, January 20, 2024

Bristol Myers Squibb, Monteverde, FGH, Therapy, Empire, PGTI, FG, KRTX, Sale, VIA, Security (finance)

Under the terms of the agreement, VIA shareholders will receive $11.00 in cash per share they own.

Key Points:

Under the terms of the agreement, VIA shareholders will receive $11.00 in cash per share they own.
Under the terms of the agreement, PGTI shareholders will receive $7.50 in common shares of Masonite and $33.50 in cash per share they own.
Under the terms of the agreement, FGH shareholders will receive one share of FG Financial common stock per share they own.
Under the terms of the agreement, KRTX shareholders will receive $330.00 in cash per share they own.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – HA, KRTX, EAR, ICVX

Retrieved on:

Tuesday, January 9, 2024

Bristol Myers Squibb, Monteverde, Therapy, EAR, Eargo, Empire, KRTX, Sale, CVR, Alaska Air Group, AstraZeneca, Hawaiian Airlines, Security (finance)

Under the terms of the agreement, HA shareholders will receive $18.00 in cash per share they own.

Key Points:

Under the terms of the agreement, HA shareholders will receive $18.00 in cash per share they own.
It is free and there is no cost or obligation to you.
Karuna Therapeutics, Inc. (Nasdaq: KRTX ), relating to its proposed sale to Bristol Myers Squibb.
Under the terms of the agreement, KRTX shareholders will receive $330.00 in cash per share they own.

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – ICVX, PGTI, KRTX, CSTR

Retrieved on:

Friday, January 5, 2024

Empire, CVR, PGTI, Sale, AstraZeneca, Monteverde, KRTX, Therapy, CSTR, Bristol Myers Squibb, Old National Bank, Security (finance)

It is free and there is no cost or obligation to you.

Key Points:

It is free and there is no cost or obligation to you.
PGT Innovations, Inc. (NYSE: PGTI ), relating to its proposed sale to Masonite International Corp.
CapStar Financial Holdings, Inc. (Nasdaq: CSTR ), relating to its proposed sale to Old National Bancorp.
Under the terms of the agreement, CSTR shareholders will receive 1.155 shares of Old National per share they own.

KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX

Retrieved on:

Sunday, December 31, 2023

Class Action Lawsuit, Professional Services, Legal, BMY, Bristol Myers Squibb, KSF, Sale, KRTX, Therapy

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY).

Key Points:

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY).
Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own.
KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

STOCKHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – SUM, KRTX, DSKE, AYX

Retrieved on:

Tuesday, December 26, 2023

Insight Partners, Empire, Sale, AYX, Monteverde, KRTX, TFI International, Therapy, Daseke, Alteryx, SUM, Bristol Myers Squibb, Security (finance)

Under the terms of the agreement, Cementos will receive approximately $1.2 billion in cash and 54.7 million shares of SUM.

Key Points:

Under the terms of the agreement, Cementos will receive approximately $1.2 billion in cash and 54.7 million shares of SUM.
Cementos will own approximately 31% of the combined company on a fully diluted basis.
Alteryx, Inc. (NYSE: AYX ), relating to its proposed sale to Clearlake Capital Group, L.P. and Insight Partners.
Under the terms of the agreement, AYX shareholders are expected to receive $48.25 in cash per share they own.

KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders

Retrieved on:

Friday, December 22, 2023

Class Action Lawsuit, Professional Services, Legal, Advertising, Fraud, Bristol Myers Squibb, Sale, KRTX, Therapy

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Karuna Therapeutics, Inc. (NASDAQ: KRTX) to Bristol Myers Squibb for $330.00 per share in cash is fair to Karuna shareholders.

Key Points:

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Karuna Therapeutics, Inc. (NASDAQ: KRTX) to Bristol Myers Squibb for $330.00 per share in cash is fair to Karuna shareholders.
On behalf of Karuna shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.